アンチトロンビン-ヘパリン共性複合体:動脈栓塞の予防のためにヘパリンに可能な代替品
Anthony K C Chan1, Janusz Rak, Leslie Berry
1Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada.
Circulation
|July 10, 2002
まとめ
新型共性抗トロンビン-ヘパリン複合体 (ATH) は,ウサギの標準ヘパリン (SH) に比べて,より優れた動脈血栓症制御を示した. ATHは,著しく少ない出血でより大きな抗血栓効果を達成し,血栓症治療の有望な代替案を提供しました.
科学分野:
- 薬理学 薬理学とは
- 心血管研究 循環器科の研究
- トロンボシスモデル
背景:
- ヘパリノイドは,アンチトロンビン (AT) とヘパリンコファクターIIのコファクター活性を通じて抗凝固効果を発揮する.
- 血栓症患者のトロンビンは,通常,標準ヘパリン (SH) 媒介による不活性化から保護されています.
- SH.の限界を克服するために,新しい共性AT-ヘパリン複合体 (ATH) が開発されました.
研究 の 目的:
- SHとATHの抗血栓性および出血性を比較する.
- ウサギの動脈血栓形成モデルでATHの有効性を評価する.
主な方法:
- ウサギの血管壁の損傷と狭窄によって誘発された動脈栓塞.
- 血液の流れは,遠端流量探知器を使用して監視されます.
- SH (62.5187.5 IU/kg) とATH (1665 IU/kg) を90分間にわたって投与する.
- 皮膚の切断による累積的な血流は安全性を評価した.
主要な成果:
- ATHは,凝固重量,血流,血管の通透性によって示された,SHよりも大きな抗血栓効果を示した.
- ATH (3365 IU/kg) とSH (125.0187.5 IU/kg) で達成された完全な血栓解像度.
- 血管の通路率 (5060%) と同等な状態では,ATHはSH (154.6 μL) よりも2.6倍少ない失血率 (60.2 μL) を誘導した.
結論:
- ATHは実験モデルでの動脈栓塞を効果的に制御しました.
- ATHは,そのSH前駆体と比較して優れた有効性を示しました.
- ATHは,顕著な出血なしに,効果的な血栓形成制御を提供しました.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis
11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K
Venous Thrombosis I: Introduction
834
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
834
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


